Author + information
- Received December 4, 2008
- Accepted December 9, 2008
- Published online February 1, 2009.
- Richard W. Troughton, MB, ChB, PhD, FRACP⁎ ( and )
- A. Mark Richards, MD, PhD, DSc, FRACP
- ↵⁎Reprint requests and correspondence:
Dr. Richard W. Troughton, University Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand
Echocardiography and the B-type natriuretic peptides (BNPs) provide powerful incremental assessment of cardiac function, clinical status, and outcome across the spectrum of cardiac disease. There is strong evidence to support their integrated use in the diagnosis and management of cardiovascular disease. Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) or BNP may guide more effective use of echocardiography in screening for asymptomatic left ventricular dysfunction; Doppler echocardiography improves the accuracy of heart failure diagnosis in the setting of intermediate BNP or NT-proBNP levels. Combined assessment of peptides and echocardiography provides more powerful stratification of risk across all stages of heart failure, and integrated use of both tests may identify subjects with valvular disease at greatest risk for progression and guide decision-making for timely intervention.
Dr. Troughton has received honoraria from Roche Diagnostics as part of their Speaker's Bureau (<$10K). Dr. Richards has received honoraria and research grants from Roche Diagnostics and Advisory Committee fees and grant support from Inverness/Biosite.
- Received December 4, 2008.
- Accepted December 9, 2008.
- American College of Cardiology Foundation
- B-type Natriuretic Peptides
- BNP and Echocardiographic Indexes of Cardiac Function
- Detection of Elevated Left Ventricular Filling Pressures
- Detection of Left Ventricular Systolic and Diastolic Dysfunction
- Diagnosis of Heart Failure
- Monitoring of Heart Failure
- Incremental Risk Assessment Using Echocardiography and B-Type Natriuretic Peptides
- Valvular Heart Disease